使用新型对比剂磁共振成像用于阿尔茨海默病早期诊断的成本效益分析

数据集获取（Figshare）

• 源站标题：Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer’'s Disease
• DOI：10.1371/journal.pone.0035559
• 发布日期：2012-04-20
• 文件数：10 个
• 文件总体积：26.34 MB
• 源站页面：https://plos.figshare.com/articles/dataset/Cost_Effectiveness_of_Magnetic_Resonance_Imaging_with_a_New_Contrast_Agent_for_the_Early_Diagnosis_of_Alzheimer_s_Disease/126362

命令行下载

curl -L -o "Figure_S1.tif" "https://ndownloader.figshare.com/files/335912"
curl -L -o "Figure_S2.tif" "https://ndownloader.figshare.com/files/335928"
curl -L -o "Figure_S3.tif" "https://ndownloader.figshare.com/files/335950"
curl -L -o "Figure_S4.tif" "https://ndownloader.figshare.com/files/335979"
curl -L -o "Figure_S5.tif" "https://ndownloader.figshare.com/files/336003"
curl -L -o "Figure_S6.tif" "https://ndownloader.figshare.com/files/336025"
curl -L -o "File_S1.docx" "https://ndownloader.figshare.com/files/336049"
curl -L -o "Table_S1.docx" "https://ndownloader.figshare.com/files/336063"

文件清单

• Figure_S1.tif（3.51 MB）
• Figure_S2.tif（1.70 MB）
• Figure_S3.tif（6.26 MB）
• Figure_S4.tif（1.61 MB）
• Figure_S5.tif（8.55 MB）
• Figure_S6.tif（4.63 MB）
• File_S1.docx（14.32 KB）
• Table_S1.docx（25.25 KB）
• Table_S2.docx（19.67 KB）
• Table_S3.docx（20.45 KB）

文件总体积 26.34 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
Used as contrast agents for brain magnetic resonance imaging (MRI), markers for beta-amyloid deposits might allow early diagnosis of Alzheimer’'s disease (AD). We evaluated the cost-effectiveness of such a diagnostic test, MRI+CLP (contrastophore-linker-pharmacophore), should it become clinically available.
Methodology/Principal Findings
We compared the cost-effectiveness of MRI+CLP to that of standard diagnosis using currently available cognition tests and of standard MRI, and investigated the impact of a hypothetical treatment efficient in early AD. The primary analysis was based on the current French context for 70-year-old patients with Mild Cognitive Impairment (MCI). In alternative “screen and treat” scenarios, we analyzed the consequences of systematic screenings of over-60 individuals (either population-wide or restricted to the ApoE4 genotype population). We used a Markov model of AD progression; model parameters, as well as incurred costs and quality-of-life weights in France were taken from the literature. We performed univariate and probabilistic multivariate sensitivity analyses.
The base-case preferred strategy was the standard MRI diagnosis strategy. In the primary analysis however, MRI+CLP could become the preferred strategy under a wide array of scenarios involving lower cost and/or higher sensitivity or specificity. By contrast, in the “screen and treat” analyses, the probability of MRI+CLP becoming the preferred strategy remained lower than 5%.
Conclusions/Significance
It is thought that anti-beta-amyloid compounds might halt the development of dementia in early stage patients. This study suggests that, even should such treatments become available, systematically screening the over-60 population for AD would only become cost-effective with highly specific tests able to diagnose early stages of the disease. However, offering a new diagnostic test based on beta-amyloid markers to elderly patients with MCI might prove cost-effective.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0035559（source: https://plos.figshare.com/articles/dataset/Cost_Effectiveness_of_Magnetic_Resonance_Imaging_with_a_New_Contrast_Agent_for_the_Early_Diagnosis_of_Alzheimer_s_Disease/126362）。